Updated on 11 February 2014
"Admedus is looking forward to an exciting 2014/15 as we launch CardioCel globally and continue to grow our sales revenue and cardiovascular teams in these regions," said Mr. Rodne.
CardioCel is engineered by the group's ADAPT tissue engineering process to be a durable, pure collagen scaffold that avoids calcification, supports native cell infiltration, growth and differentiation and which promotes a regenerative healing process.
CardioCel has shown benefits over existing products in that it does not calcify like other tissue products and has shown to facilitate autologous tissue regeneration once surgically implanted, while retaining strength and natural elasticity. CardioCel is a ready to use, off the shelf product that has the potential to prevent follow up surgeries for patients because of its anti-calcification and regenerative properties.